This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Inolimomab
DrugBank Accession Number
DB15628
Background

Inolimomab is under investigation as an agent to treat steroid-resistant graft vs host disease. It has thus far offered similar efficacy to other monoclonal antibody options, though it may carry a higher risk of infections.1

Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Protein Chemical Formula
Not Available
Protein Average Weight
Not Available
Sequences
Not Available
Synonyms
  • Immunoglobulin G1, anti-(human interleukin 2 receptor alpha-chain) (mouse monoclonal B-B10 gammal-chain), disulfide with mouse monoclonal B-B10 kappa-chain, dimer
  • Inolimomab
External IDs
  • BT-563

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action

Inolimomab is a murine monoclonal antibody targeting CD-25, also known as the alpha subunit of the interleukin-2 receptor. 3 The binding of this antibody to CD-25 blocks the signaling of interleukin-2, preventing clonal expansion of T-cells. The resulting immunosuppressive effect appears to provide a similar benefit in patients with steroid-resistant graft vs host disease to anti-thymocyte globulin.2

TargetActionsOrganism
UInterleukin-2 receptor subunit alpha
antibody
Humans
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbataceptThe risk or severity of adverse effects can be increased when Abatacept is combined with Inolimomab.
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Inolimomab.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Inolimomab.
Adenovirus type 7 vaccine liveThe risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Inolimomab.
AducanumabThe risk or severity of adverse effects can be increased when Aducanumab is combined with Inolimomab.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Inolimomab.
AlefaceptThe risk or severity of adverse effects can be increased when Alefacept is combined with Inolimomab.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Inolimomab.
AlirocumabThe risk or severity of adverse effects can be increased when Alirocumab is combined with Inolimomab.
Allogeneic processed thymus tissueThe therapeutic efficacy of Allogeneic processed thymus tissue can be decreased when used in combination with Inolimomab.
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
International/Other Brands
Leukotac

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
GO90DFK14U
CAS number
152981-31-2

References

General References
  1. Shen MZ, Li JX, Zhang XH, Xu LP, Wang Y, Liu KY, Huang XJ, Hong SD, Mo XD: Meta-Analysis of Interleukin-2 Receptor Antagonists as the Treatment for Steroid-Refractory Acute Graft-Versus-Host Disease. Front Immunol. 2021 Sep 21;12:749266. doi: 10.3389/fimmu.2021.749266. eCollection 2021. [Article]
  2. Socie G, Vigouroux S, Yakoub-Agha I, Bay JO, Furst S, Bilger K, Suarez F, Michallet M, Bron D, Gard P, Medeghri Z, Lehert P, Lai C, Corn T, Vernant JP: A phase 3 randomized trial comparing inolimomab vs usual care in steroid-resistant acute GVHD. Blood. 2017 Feb 2;129(5):643-649. doi: 10.1182/blood-2016-09-738625. Epub 2016 Nov 29. [Article]
  3. ElsaLys Biotech: What is inolimomab (LEUKOTAC®)? [Link]
Wikipedia
Inolimomab

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3Not Yet RecruitingTreatmentSteroid Refractory GVHD1
Not AvailableAvailableNot AvailableSteroid Resistant Acute Graft Versus Host Disease1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Antibody
General Function
Interleukin-2 receptor activity
Specific Function
Receptor for interleukin-2. The receptor is involved in the regulation of immune tolerance by controlling regulatory T cells (TREGs) activity. TREGs suppress the activation and expansion of autorea...
Gene Name
IL2RA
Uniprot ID
P01589
Uniprot Name
Interleukin-2 receptor subunit alpha
Molecular Weight
30818.915 Da

Drug created at March 07, 2020 20:00 / Updated at November 08, 2021 03:40